Novartis AG
REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIA ANTIBODIES AND USES THEREOF

Abstract:

The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies (e.g., NOV1401), and to related methods for managing bleeding or bleeding risks.